An LC–MS/MS method for simultaneous determination of curcumin, curcumin glucuronide and curcumin sulfate in a phase II clinical trial

Journal of Pharmaceutical and Biomedical Analysis

Volumn 156, Issue , 2018, Pages 189-198

  Kunati, Sandeep R ^a   Yang, Shuming ^b   William, Basem M ^c   Xu, Yan ^a,b  

^a CLEVELAND STATE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Curcumin; Curcumin glucuronide; Curcumin sulfate; Human plasma; LC MS MS; Method validation

Indexed keywords

COLECALCIFEROL; CURCUMIN; CURCUMIN GLUCURONIDE; CURCUMIN SULFATE; GLUCURONIDE; SULFATE; UNCLASSIFIED DRUG; METHANOL;

ARTICLE; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; EARLY CANCER; ELECTROSPRAY; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LYMPHOCYTIC LYMPHOMA; MULTIPLE REACTION MONITORING; PH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; ADULT; ANALOGS AND DERIVATIVES; BLOOD; CALIBRATION; CHEMISTRY; DEVICES; ELECTROSPRAY MASS SPECTROMETRY; PHASE 2 CLINICAL TRIAL (TOPIC); PROCEDURES; REPRODUCIBILITY; STANDARD; VALIDATION STUDY; YOUNG ADULT;

ADULT; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS, PHASE II AS TOPIC; CURCUMIN; GLUCURONIDES; HUMANS; METHANOL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SULFATES; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 85046362532     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2018.04.034     Document Type: Article

References (21)

1. Singh, S., From exotic spice to modern drug?. Cell 130 (2007), 765–768.
2. Aggarwal, B.B., Sung, B., Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol. Sci. 30 (2009), 85–94.
3. Maheshwari, R.K., Singh, A.K., Gaddipati, J., Srimal, R.C., Multiple biological activities of curcumin: a short review. Life Sci. 78 (2006), 2081–2087.
4. Anand, P., Kunnumakkara, A.B., Newman, R.A., Aggarwal, B.B., Bioavailability of curcumin: problems and promises. Mol. Pharm. 4 (2007), 807–818.
5. Cheng, A.L., Hsu, C.H., Lin, J.K., Hsu, M.M., Ho, Y.F., Shen, T.S., Ko, J.Y., Lin, J.T., Lin, B.R., Wu, M.S., Yu, H.S., Jee, S.H., Chen, G.S., Chen, T.M., Chen, C.A., Lai, M.K., Pu, Y.S., Pan, M.H., Wang, Y.J., Tsai, C.C., Hsieh, C.Y., Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21 (2001), 2895–2900.
6. Prasad, S., Tyagi, A.K., Aggarwal, B.B., Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res. Treat. 46 (2014), 2–18.
7. Lao, C.D., Ruffin, M.T., Normolle, D., Heath, D.D., Murray, S.I., Bailey, J.M., Boggs, M.E., Crowell, J., Rock, C.L., Brenner, D.E., Dose escalation of a curcuminoid formulation. BMC Complement. Altern. Med., 6, 2006, 10.
8. Mohandas, K.M., Desai, D.C., Epidemiology of digestive tract cancers in India. V. Large and small bowel. Indian J. Gastroenterol. 18 (1999), 118–121.
9. Vallianou, N.G., Evangelopoulos, A., Schizas, N., Kazazis, C., Potential anticancer properties and mechanisms of action of curcumin. Anticancer Res. 35 (2015), 645–652.
10. Wilken, R., Veena, M.S., Wang, M.B., Srivatsan, E.S., Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol. Cancer 10 (2011), 1–19.
11. Syng-Ai, C., Kumari, A.L., Khar, A., Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2. Mol. Cancer Ther. 3 (2004), 1101–1108.
12. ClinicalTrials. gov, National Library of Medicine (US), Identifier NCT02100423: Curcumin and Cholecalciferol in Treating Patients with Previously Untreated Stage 0–11 Chronic Lympocytic Leukemia or Small Lymphocytic Lymphoma. 2018 Available from: https://www.clinicaltrials.gov/ct2/show/NCT02100423. (Accessed on 02.12.2018).
13. CASE 5913, A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early-stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). 2018, Case Comprehensive Cancer Center, Cleveland, OH, USA.
14. Wang, X., Zhang, Q., Yang, J., Zhu, R., Zhang, J., Cai, L., Peng, W., Validated HPLC–MS/MS method for simultaneous determination of curcumin and piperine in human plasma. Trop. J. Pharm. Res. 11 (2012), 621–629.
15. Vareed, S.K., Kakarala, M., Ruffin, M.T., Crowell, J.A., Normolle, D.P., Djuric, Z., Brenner, D.E., Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol. Biomarkers Prev. 17 (2008), 1411–1417.
16. Cao, Y., Xu, R.X., Liu, Z., A high-throughput quantification method of curcuminoids and curcumin metabolites in human plasma via high-performance liquid chromatography/tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 949–950 (2014), 70–78.
17. Lestari, M.L.A.D., Indrayanto, G., Curcumin. Brittain, H., (eds.) Profiles of Drug Substances, Excipients and Related Methodology, 2014, Academic Press, San Diego, CA, 13–204.
18. Snoble, K.A., Fox, N.M., Lorenz, S.M., Kemperman, A.R., Przybytek, J., Stability of formic acid in methanol solutions and the implications for use in LC-MS gradient elution analysis. LC GC North America 26 (2008), 946–950.
19. Gupta, S.C., Patchva, S., Aggarwal, B.B., Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 15 (2012), 195–218.
20. Wu, Z., Gao, W., Phelps, M.A., Wu, D., Miller, D.D., Dalton, J.T., Favorable effects of weak acids on negative-Ion electrospray ionization mass spectrometry. Anal. Chem. 76 (2004), 839–847.
21. Food, U.S., Drug Administration Guidance for Industry, Bioanalytical Method Validation. 2001 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf. (Accessed on 02.12.2018).